Journal of Lipid Research, Vol 28, 684-692, Copyright © 1987 by Lipid Research, Inc.

ARTICLES

Blockade of intestinal lipoprotein clearance in rabbits injected with Triton WR 1339-ethyl oleate

Y Nagata and DB Zilversmit

Although Triton WR 1339 has been used to block triglyceride or cholesterol removal from plasma, no data are available on the extent to which Triton WR 1339 administered to rabbits blocks clearance of newly absorbed dietary lipids. In the present study, we have measured the efficiency of this blockade during a 24-hr interval. After the Triton WR 1339 administration, plasma Sf greater than 400 and d less than 1.019 g/ml lipoprotein lipid concentrations increased greatly, but the concentration of d greater than 1.019 g/ml lipids decreased. In the rabbits fed 0.5% cholesterol for 1 week, the increase in d less than 1.019 g/ml and the decrease in 1.019 less than d less than 1.063 g/ml lipoprotein fractions 24 hr after the Triton WR 1339 injection were much greater than in the chow-fed Tritonized rabbits. After the Triton treatment, 50% of intravenously injected LDL-125I-labeled apoB disappeared in 24 hr, but little or no apoB appeared in other lipoprotein fractions and no VLDL apoB was converted to LDL. Labeled cholesterol and retinol were fed to rabbits and 24-hr increments in plasma cholesteryl- and retinyl-ester label and mass were measured. In chow-fed Tritonized rabbits about one-half of the absorbed oral doses of both labeled lipids was recovered in plasma, indicating that Triton WR 1339 does not completely inhibit the clearance of intestinal lipoproteins. When rabbits were injected with Triton and an ethyl oleate emulsion, the blockade of dietary lipid removal from plasma was substantially improved and chylomicron cholesterol uptake by extra- hepatic tissues was completely abolished.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. J. Kirby, P. N. Howles, and D. Y. Hui Rate of gastric emptying influences dietary cholesterol absorption efficiency in selected inbred strains of mice J. Lipid Res., January 1, 2004; 45(1): 89 - 98. [Abstract] [Full Text] [PDF]

				G. Haraguchi, Y. Kobayashi, M. L. Brown, A. Tanaka, M. Isobe, S. H. Gianturco, and W. A. Bradley PPAR{alpha} and PPAR{gamma} activators suppress the monocyte-macrophage apoB-48 receptor J. Lipid Res., June 1, 2003; 44(6): 1224 - 1231. [Abstract] [Full Text] [PDF]

				T. M. Riddle, N. M. Schildmeyer, C. Phan, C. J. Fichtenbaum, and D. Y. Hui The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice J. Lipid Res., September 1, 2002; 43(9): 1458 - 1463. [Abstract] [Full Text] [PDF]

				M. L. Brown, M. P. Ramprasad, P. K. Umeda, A. Tanaka, Y. Kobayashi, T. Watanabe, H. Shimoyamada, W.-L. Kuo, R. Li, R. Song, et al. A macrophage receptor for apolipoprotein B48: Cloning, expression, and atherosclerosis PNAS, June 13, 2000; (2000) 120184097. [Abstract] [Full Text]

				S. H. Gianturco, M. P. Ramprasad, R. Song, R. Li, M. L. Brown, and W. A. Bradley Apolipoprotein B-48 or Its Apolipoprotein B-100 Equivalent Mediates the Binding of Triglyceride-Rich Lipoproteins to Their Unique Human Monocyte-Macrophage Receptor Arterioscler. Thromb. Vasc. Biol., June 1, 1998; 18(6): 968 - 976. [Abstract] [Full Text] [PDF]

				M. L. Brown, M. P. Ramprasad, P. K. Umeda, A. Tanaka, Y. Kobayashi, T. Watanabe, H. Shimoyamada, W.-L. Kuo, R. Li, R. Song, et al. A macrophage receptor for apolipoprotein B48: Cloning, expression, and atherosclerosis PNAS, June 20, 2000; 97(13): 7488 - 7493. [Abstract] [Full Text] [PDF]